Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| PELyon | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Since March 2020, 3.5 million people have been infected with SARS-COV2 in France, and about 250 000 patients have been hospitalized and successfully discharged.
In a majority of cases, the evolution of the disease is favourable, but both hospitalized or patients with a mild form of the disease may present so called "Long-COVID" syndrome - a patient-created term which describes the effects of COVID-19 that continue for weeks or months beyond the initial symptoms. There is thus an urgent need to evaluate the long-term medical resource utilisation (MRU) and health care burden incurred by patients with Long-COVID, as well as risk factors for Long-COVID.
We will use the SNDS database to extract and analyze the data relevant to the project objectives. Indeed, the SNDS database is the French NHS database providing individual anonymous information of primary and secondary care linked at individual level (data from PMSI, the French DRG-based medical information system). It currently covers more than 98% of the French population.
For the first time, our study will provide an estimation of MRU and associated costs of hospitalized COVID-19 patients. It will also provide an estimation of the rate of long COVID forms developed by hospitalized COVID patients, as well as detailed MRU and costs incurred by long COVID patients compared to patients with non-long COVID-19.
Since March 2020, 3.5 million people have been infected with SARS-COV2 in France, and about 250 000 patients have been hospitalized and successfully discharged . Currently, the French epidemiological situation shows a stable and high level of new cases of COVID-19 (around 20 000 per day) and associated hospitalizations (around 9 000 per week).
COVID19 may present mild or severe forms, the latter possibly requiring conventional (20%) or intensive care unit (ICU) hospitalization (5%). In most cases, the evolution of the disease is favorable, but both hospitalized or patients with a mild form of the disease may present so called "Long-COVID" syndrome - a patient-created term which describes the effects of COVID-19 that continue for weeks or months beyond the initial symptoms. Persistent symptoms have been described in 5 to 36% of the patients, i.e. symptoms persisting for 4 weeks or more after the onset of the disease. There is growing evidence of the post-COVID-19 chronic syndrome as a postinfectious entity, including but not limited to a range of symptoms ranging from cough and shortness of breath, to fatigue, headache, palpitations, chest pain, joint pain, physical limitations, depression, and insomnia, persisting for longer than two months. This post-COVID chronic syndrome is often called "long COVID". As it is more and more described since the start of the pandemic, the French national health agency (Haute Autorité de Santé, HAS) has recently published specific recommendations for the management of patients presenting long COVID forms.
Although the evidence is still scarce, patients who have been hospitalized for COVID19 may be at higher risk of presenting long COVID. Consequently, they may require more healthcare resource use. As they are easy to identify through administrative databases, we propose to focus on hospitalized and discharged COVID-19 patients with persisting symptoms, in order to investigate their healthcare resource use and corresponding costs, and to compared them to patients not presenting the long COVID form of the disease.
The objectives of this study are:
This will be performed using the Système National des Données de Santé (SNDS) French medico-administrative database.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 patients | COVID-19 patients discharged from all French hospitals from 01 February to 30 June 2020 |
| |
| sub group The "long COVID" patients | this cohort will include patients with at least 4 weeks of claims and specific health care use after hospital admission from the initial cohort (COVID-19 patients) According to the Haute Autorité de Santé (HAS), the most frequent symptoms in the context of long COVID are the following :
|
| |
| sub group "non long COVID" patients | all other patients from the initial cohort (COVID-19 patients ) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COVID-19 required hospitalisation | Other | Patients who contracted a COVID19 required hospitalisation |
|
| Measure | Description | Time Frame |
|---|---|---|
| MRU (medical resource use ) | The primary outcome will be the description of MRU and related costs during the 6 months following the discharge date, i.e.:
| 6 months following the discharge date |
| Measure | Description | Time Frame |
|---|---|---|
| Predictive variables for "long-COVID" | identified risk factors for developing long-COVID | up to 1 year before the hospitalisation date |
| Patterns of long-COVID healthcare consumption | typologies of consumption (cluster analyses) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult COVID-19 patients discharged from all French hospitals from 01 February to 30 June 2020
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mikhail DZIADZKO, MD, PhD | Hospices Civils de Lyon | Principal Investigator |
| Frederic Aubrun, MD, PhD | Hospices Civils de Lyon | Principal Investigator |
| Eric VAN-GANSE, MD, PhD | Hospices Civils de Lyon | Principal Investigator |
| Pierre ALBALADEJO, MD, PhD | CHU Grenoble Alpes | Study Chair |
| Florence ADER, MD, PhD | Hospices Civils de Lyon | Study Chair |
| Valeria MARTINEZ, MD, PhD | Hôpital Raymond-Poincaré - APHP | Study Chair |
| Claire MARANT-MICALLEF, PharmD, MPH | PELyon | Study Director |
| Manon BELHASSEN, MD, PhD | PELyon | Study Director |
| Fabrice HERITIER, MD | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital de la Croix Rousse - Hospices Civils de Lyon | Lyon | 69004 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39259961 | Derived | Dziadzko M, Belhassen M, Van Ganse E, Heritier F, Berard M, Marant-Micallef C, Aubrun F. Health Care Resource Use and Total Mortality After Hospital Admission for Severe COVID-19 Infections During the Initial Pandemic Wave in France: Descriptive Study. JMIR Public Health Surveill. 2024 Sep 11;10:e56398. doi: 10.2196/56398. |
Not provided
Not provided
individual participant data are protected by the French legislation and are not shared
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000094024 | Post-Acute COVID-19 Syndrome |
| D059350 | Chronic Pain |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months following the discharge date |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |